Merrimack Pharmaceuticals
MACK
$14.98
Share price
1.63%
Change (1 day)
18.98%
Change (1 year)
Categories
Merrimack Pharmaceuticals (MACK) - Cash on Hand
Cash on Hand as of December 2023 : $18.87 M
According to Merrimack Pharmaceuticals's latest financial reports the company has $18.87 M in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Merrimack Pharmaceuticals - Cash on Hand chart (from 2010 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $18.87 M | -2.9% |
| 2022-12-31 | $19.43 M | 36.87% |
| 2021-12-31 | $14.2 M | 1.18% |
| 2020-12-31 | $14.03 M | -15.33% |
| 2019-12-31 | $16.58 M | -76.74% |
| 2018-12-31 | $71.27 M | -23.72% |
| 2017-12-31 | $93.44 M | 334.12% |
| 2016-12-31 | $21.52 M | -88.4% |
| 2015-12-31 | $0.18 B | 49.65% |
| 2014-12-31 | $0.12 B | -20.09% |
| 2013-12-31 | $0.15 B | 41.15% |
| 2012-12-31 | $0.10 B | 117.93% |
| 2011-12-31 | $50.45 M | 64.28% |
| 2010-12-31 | $30.71 M | -47.4% |
| 2009-12-31 | $58.38 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $9.92 B | 52,499.42% | 🇫🇷 France |
 Geron GERN | $0.33 B | 1,667.94% | 🇺🇸 USA |
 Clovis Oncology CLVS | $58.32 M | 208.98% | 🇺🇸 USA |
 AVEO Oncology
AVEO | $77.39 M | 310.06% | 🇺🇸 USA |
 Eterna Therapeutics ERNA | $7.57 M | -59.87% | 🇺🇸 USA |